ArticleSchizophrenia bulletin2026
Can Polygenic Risk Scores for Metabolic Syndrome Contribute to Long-Term Syndrome Development in First-Episode Psychosis Patients? A Naturalistic 21-Year Follow-Up Study.
Article in Schizophrenia bulletin, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
background and hypothesisMetabolic syndrome (MetS) is still a challenge for clinicians treating patients with first-episode psychosis (FEP). STUDY
designWe explored whether polygenic risk scores for MetS (PRSMetS) may be associated with MetS in FEP patients. The sample comprised 164 FEP patients who were followed-up for a mean of 20.9 years. MetS was defined according to the ATP III criteria at the end of the follow-up. We used logistic regression models to examine the contribution of PRSs for the development of MetS and associated metabolic symptoms after allowing for the effect of covariates. Furthermore, we investigated the relationships between PRSMetS and metabolic symptoms using network analysis (NA). STUDY
resultsPRSMetS significantly contributed to the development of MetS and the increase of waist circumference at the long-term follow-up, accounting for 7.9% and 6.8% of the explained variance, respectively. Moreover, the PRS of high-density lipoprotein cholesterol levels showed a significant association value for hypertension, accounting for 5.6% of the variance.PRSMetS showed a significant linear trend with the number of MetS criteria and this trend remained significant after allowing for standard epidemiological and clinical baseline variables in the hierarchical multiple regression analysis. PRSMetS, PRSWaist, and the five metabolic criteria showed rich interconnections in the network analysis.
conclusionsMetS PRSs showed significant relationships with metabolic disturbances in patients with FEP over a lifetime. Our findings may offer promising avenues for the PRSMetS to be integrated with relevant clinical measures for identifying the FEP patients most vulnerable to develop MetS.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.